Navigation Links
Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
Date:1/28/2009

CAMBRIDGE, England, January 28 /PRNewswire/ -- Phico Therapeutics today announced it has been granted a Wellcome Trust Strategic Translational Award totalling GBP1.03 million to cover Phase I and II trials of its lead candidate SASPject(TM) PT1.2 for nasal decolonisation of MRSA and S. aureus. PT1.2 is based on a new class of antibacterial proteins called SASPs which bind to bacterial DNA resulting in rapid "speed of kill". Phico envisages developing a fast-acting, easily applicable nasal gel which would combat both hospital S. aureus infection and hospital and community MRSA transmission and drug-resistance.

According to Phico Therapeutics CEO and founder, Dr Heather Fairhead, there is a clear need for such a product. "Whilst hospitals have introduced stricter cleaning regimes, the twin problems of transmission and drug-resistance remain. We already demonstrated last year in several studies, including some carried out in conjunction with the UK's Health Protection Agency, that PT1.2 is rapidly bactericidal against more than 200 clinical S. aureus and MRSA isolates, spanning the known MRSA types in Europe and the US. Indeed in the speed of kill assay, SASP caused a greater than or equal to 99.9 % drop in viability within 2 minutes against a 10(5) culture and a greater than or equal to 99.9 % drop in viability within 10 minutes against a 10(7) culture of a major US MRSA strain. I am delighted that the Wellcome Trust see the potential of PT1.2. This award will enable us to conduct phase I and II clinical trials with results expected Q3 2009 and Q3 2010 respectively."

Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust commented: "There is an urgent need to develop innovative ways to manage the transmission of antibiotic-resistant bacteria in the hospital and care-home environments. The approach being taken by Dr Fairhead and colleagues is imaginative and original. If successful, this tech
'/>"/>

SOURCE Phico Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014   Plexus Information ... of Anesthesia Information Management Systems (AIMS), announced a ... , a wholly owned subsidiary of Quality Systems, ... systems and connectivity solutions.  Logo ... This partnership extends the ...
(Date:10/1/2014)... -- ResMed (NYSE: RMD ), a pioneer and innovator ... complete sleep apnea solutions specifically for women, is launching a ... good night,s sleep. The Better Sleep For ... is just part of living a busy life. It will ... of health, essential to not only living an active lifestyle ...
(Date:10/1/2014)... 2014 Trovagene, Inc., (NASDAQ:  TROV) a ... Eli Diamond , MD, Assistant Attending Neurologist ... clinical data from an ongoing study demonstrating the ... the determination of oncogene mutational status in cell-free ... were presented to both treating physicians and patients ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... SAN DIEGO, July 9 Arena Pharmaceuticals, ... results from a multiple-ascending,dose Phase 1b clinical ... safety,pharmacokinetics and pharmacodynamics. APD791 is Arena,s internally,discovered ... of arterial,thrombosis and other related conditions., ...
... July 8 After meeting on July 1st ... new diabetes drugs should,undergo trials to rule out ... US endocrinologists agree with this recommendation, according to,AlphaDetail ... market,research and key opinion leader mapping solutions to ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 4Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 5AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panel's Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications. 2
(Date:10/2/2014)... October 02, 2014 Social-Engineer, Inc. the ... announced today it will host a complimentary webinar on ... will reveal the final outcome of the annual Social-Engineer ... 22 in Las Vegas and explore how to maximize ... attacks. To register for the webinar go to: ...
(Date:10/2/2014)... Norton HealthDay Reporter WEDNESDAY, ... birth control -- especially long-acting implanted devices -- could slash ... average, new findings suggest. In a study of 1,400 ... cut the girls, rates of unplanned pregnancy and abortion. Over ... girls -- versus a rate of 158 per 1,000 among ...
(Date:10/2/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... major highway may raise your risk for high blood pressure, ... women, those who lived within 109 yards of a busy ... blood pressure than women living at least half a mile ... highlight the importance of our physical environment on our health ...
(Date:10/2/2014)... at The University of Nottingham could lead to the ... A drug resulting from the research, published in the ... hope to sufferers of chronic pain conditions such as ... currently available. , The work, led by Dr Lucy ... collaboration with David Bates, Professor of Oncology in the ...
(Date:10/1/2014)... the brain of a rat and a robot could ... QUT leading robotics researcher. , Dr Michael Milford ... study uses new computer algorithms to enable robots to ... "This is a very Frankenstein type of project," Dr ... thing together because we,re taking the eyes of a ...
Breaking Medicine News(10 mins):Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 2Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 3Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 2Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 3Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 4Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:Medical discovery first step on path to new painkillers 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2
... of a landmark study, researchers at Mayo Clinic,s Florida campus ... need to remove colon polyps that are not cancerous or ... to one-half of the polyps removed during colonoscopies end up ... and this increases time, expense and the potential for complications ...
... amo, a destination spa,at Enchantment Resort, for a ... winter solstice on December 21. Activities include a,series ... Program Director R.J. Joseph and special guest, Elder ... from the Blood Reserve,in Standoff, Alberta, Canada,s largest ...
... announcement of planned bequest comes at stem cell symposium, ... one year,ago, retail pioneer A. Alfred Taubman announced a ... a new research institute aimed at,understanding, treating and preventing ... he did it again --,announcing that he will bequeath ...
... Wanted to Know But Was Afraid to Ask!, ... babies born,in the U.S. each year but there,s not ... is a revealing, entertaining and inspirational DVD that,offers invaluable ... gone through the pregnancy and delivery process. It includes,a ...
... LAKE CITY University of Utah researchers have developed a ... to the wall of the heart,s left atrium in patients ... results of the study are published in the Oct. 7, ... of Cardiology . , Atrial fibrillation (AF) is an ...
... ) (OTCBB:WYND), the ideas-to-revenues social media company, ... ( www.muveinc.com ), to create an interactive ... activity-based corporate wellness program. Wyndstorm,s design project ... the use of wellness programs among employees ...
Cached Medicine News:Health News:Mayo Clinic estimates new, tiny, super-sensitive probe could cut colon polyp removal in half 2Health News:Mii amo Honors Winter Solstice With Traditional Native American Celebration December 18-21 2Health News:Alfred Taubman Announces New $22M Gift to U-M 2Health News:BEING DAD DVD Offers a Sneak Peek at Pregnancy From a Guy's Point of View 2Health News:Novel imaging approach may assist in predicting success of treatment for atrial fibrillation 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: